Hypertension
Conditions
Brief summary
To investigate the effects of Candesartan and Telmisartan on the home blood pressure, glucose and lipid-metabolism in the hypertensive patients with the accumulation of visceral fat by the newly developed Tele-medicine system
Detailed description
A randomized, comparative study of the effects of Candesartan and Telmisartan on the home blood pressure, glucose and lipid metabolism in the hypertensive patients with the accumulation of visceral fat by the central registration system
Interventions
DRUGCandesartan
DRUGTelmisartan
Sponsors
Non-Profit Organaizaion LINE
Saitama Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Circumference at waist: male ≧85 cm, female ≧90 cm * Hypertensive patient with untreated hypertension, and casual blood pressure of systole ≧140 mmHg, or diastole ≧90 mmHg * Hypertensive patient with hypertension under treatment, and casual blood pressure of systole ≧130 mmHg, or diastole ≧85 mmHg
Exclusion criteria
* Significant hypertensive patient with diastolic blood pressure ≧120 mmHg * Malignant hypertensive patient * Patient with a contraindication to the study drugs (hypersensitivity, significant hepatic diseases, pregnant woman) * Patient with urinary protein (qualitative) ＋～＋＋ * Patient with familial hyperlipidemia * Other patients judged as ineligible for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Home blood pressure in the early morning | — |
Secondary
| Measure | Time frame |
|---|---|
| M/E ratio | — |
| Casual blood pressure | — |
| Body fat percentage | — |
| Body weight | — |
| Height | — |
| BMI | — |
| Blood potassium | — |
| Total cholesterol | — |
| Home blood pressure at bedtime | — |
| LDL cholesterol | — |
| Triglyceride | — |
| Blood glucose | — |
| IRI | — |
| HbAlc* | — |
| HOMA-IR | — |
| Urinary trace albumin | — |
| Creatinine | — |
| HDL cholesterol | — |
Countries
Japan
Contacts
Primary ContactHidetomo Nakamoto, MD
Outcome results
None listed